Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment

SIMPLE SUMMARY: Regorafenib has proven its efficacy for later-line treatment of mCRC. However, treatment often brings substantial toxicities that lead clinicians to assess the risk-to-benefit ratio in heavily pretreated patients. Thus, it is crucial to develop a prognostic factor and model for guidi...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yu-Li, Tsai, Kai-Lung, Chiu, Tai-Jan, Lin, Yueh-Ming, Lee, Ko-Chao, Lu, Chien-Chang, Chen, Hong-Hwa, Wu, Chia-Che, Hsu, Hung-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533782/
https://www.ncbi.nlm.nih.gov/pubmed/34680230
http://dx.doi.org/10.3390/cancers13205080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533782/
https://www.ncbi.nlm.nih.gov/pubmed/34680230
http://dx.doi.org/10.3390/cancers13205080

Ejemplares similares